Impact BioMedical
24 hedge funds and large institutions have $726K invested in Impact BioMedical in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
103% more capital invested
Capital invested by funds: $358K → $726K (+$368K)
14% more funds holding
Funds holding: 21 → 24 (+3)
7.4% more ownership
Funds ownership: 4.42% → 11.82% (+7.4%)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$377K |
| 2 |
Millennium Management
New York
|
+$72.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$15.5K |
| 4 |
Jane Street
New York
|
+$7.45K |
| 5 |
HF
HRT Financial
New York
|
+$7.16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$9.48K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$3.04K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.36K |
| 4 |
Citigroup
New York
|
-$1.8K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$24 |
IBO Hedge Fund Activity: Q4 2025 in Review
24 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in Impact BioMedical (IBO) for Q4 2025, worth a combined $726K — up 103% from $358K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new IBO positions and 1 closed out — a net gain of 3 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $377K. The largest seller was UBS Group, cutting an estimated $9.48K.
- 24 institutional investors held Impact BioMedical (IBO) as of Q4 2025, up from 21 in Q3 2025.
- Funds reported $726K of Impact BioMedical stock for Q4 2025, up 103% quarter-over-quarter.
- 4 funds opened new Impact BioMedical positions in Q4 2025 and 1 closed out, a net change of +3 holders.
- The largest Impact BioMedical buyer in Q4 2025 was Vanguard Group, an estimated $377K added.
- The largest Impact BioMedical seller in Q4 2025 was UBS Group, an estimated $9.48K sold.
Based on aggregated 13F filings for Q4 2025.